Artificial intelligence-based evaluation of prognostic benefits from immunotherapy plus targeted therapy with or without radiotherapy or TACE in advanced hepatocellular carcinoma
Immunotherapy plus targeted therapy combined with TACE or RT significantly improved survival in advanced HCC compared with systemic therapy alone. RSF provided superior predictive performance and identified critical prognostic variables, supporting AI-assisted approaches as valuable tools for individualized risk stratification and treatment optimization in advanced HCC.
Authors
- Shanshan Lu (ORCID: https://orcid.org/0000-0001-6270-9347)
- Yuqian Yang (ORCID: https://orcid.org/0000-0002-4948-8428)
- Xueting Li (ORCID: https://orcid.org/0000-0002-6868-5929)
- Huarong Zhao (ORCID: https://orcid.org/0000-0002-7247-1165)
- Shiqin Song
- Yuehong Deng
Institutions
- Sichuan Cancer Hospital (CN)
- Chongqing Emergency Medical Center (CN)
- Qujiang People's Hospital (CN)
- First People's Hospital of Chongqing (CN)
- Lu'an First People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.3389/fonc.2025.1694565
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00